IL2 and metastatic neoplasm: We conducted a therapeutic trial with YM155 alone, IL-2 alone, and the combination of YM155 with IL-2 to determine their antitumor effects on the progression of both orthotopic and lung metastatic tumors in a luciferase-expressing RENCA mouse model of RCC.